# TiGenix

its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn's disease, and Takeda provides periodic updates on the programme as the EU's lead commercial autoimmune-MSC asset.

Source: https://en.bioecon.ru/companies/tigenix/
Updated: 2026-07-20

- Country: Spain

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Takeda acquired TiGenix in 2018 for approximately €520 million | https://talent24h.okdiario.com/el-cierre-de-la-planta-biotecnologica-de-takeda-en-tres-cantos-madrid-deja-en-el-aire-el-futuro-de-120-trabajadores-cualificados/ |
| Capacity | Production capacity in Spain was tripled following a €10.6 million investment in 2021 | https://gacetamedica.com/investigacion/takeda-invierte-106-millones-ante-el-aumento-de-la-demanda-del-medicamento-vivo-comercializado/, https://www.takeda.com/es-es/sala-de-prensa/2021/takeda-triplica-la-capacidad-de-su-planta-de-fabricacion-en-espana-para-asumir-el-aumento-de-demanda-mundial-de-la-primera-terapia-celular-alogenica/ |
| Regulatory approval | Alofisel received European Commission marketing authorization in March 2018 | https://www.prnewswire.com/news-releases/tigenix-and-takeda-announce-alofisel-darvadstrocel-receives-approval-to-treat-complex-perianal-fistulas-in-crohns-disease-in-europe-677763453.html, https://www.takeda.com/newsroom/newsreleases/2018/tigenix-and-takeda-announce-alofisel-receives-approval-in-europe/ |
| Production site | Manufacturing plant located in Tres Cantos, Madrid, which closed following the cessation of Alofisel production in 2026 | https://gacetamedica.com/investigacion/takeda-invierte-106-millones-ante-el-aumento-de-la-demanda-del-medicamento-vivo-comercializado/, https://talent24h.okdiario.com/el-cierre-de-la-planta-biotecnologica-de-takeda-en-tres-cantos-madrid-deja-en-el-aire-el-futuro-de-120-trabajadores-cualificados/, https://www.redaccionmedica.com/empresas/industria-farmaceutica/20260218/takeda-cierra-su-fabrica-en-espana-por-el-cese-de-produccion-alofisel/258256_0.html, https://www.takeda.com/es-es/sala-de-prensa/2021/takeda-triplica-la-capacidad-de-su-planta-de-fabricacion-en-espana-para-asumir-el-aumento-de-demanda-mundial-de-la-primera-terapia-celular-alogenica/ |
| Headcount | The Tres Cantos facility employed approximately 120 people as of February 2026 | https://madridinforma.eldiario.es/takeda-desinvierte-en-su-centro-biotecnologico-de-madrid-y-deja-120-empleos-en-el-aire/, https://talent24h.okdiario.com/el-cierre-de-la-planta-biotecnologica-de-takeda-en-tres-cantos-madrid-deja-en-el-aire-el-futuro-de-120-trabajadores-cualificados/, https://www.redaccionmedica.com/empresas/industria-farmaceutica/20260218/takeda-cierra-su-fabrica-en-espana-por-el-cese-de-produccion-alofisel/258256_0.html |
| Revenue | Takeda reported annual sales of 4.26 trillion yen for 2024 | https://madridinforma.eldiario.es/takeda-desinvierte-en-su-centro-biotecnologico-de-madrid-y-deja-120-empleos-en-el-aire/, https://talent24h.okdiario.com/el-cierre-de-la-planta-biotecnologica-de-takeda-en-tres-cantos-madrid-deja-en-el-aire-el-futuro-de-120-trabajadores-cualificados/ |

Independent sources: gacetamedica.com, madridinforma.eldiario.es, prnewswire.com, redaccionmedica.com, takeda.com, talent24h.okdiario.com

## Technologies

- [Stem cell therapy for autoimmune disease](https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/)